Clinical trial NCT00441558: A One-year Safety Study of Flibanserin to Treat Pre-Menopausal Women With Hypoactive Sexual Desire Disorder (HSDD).
Official title: Worldwide One-year Open-label Safety Study of Flibanserin in Women With HSDD
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Sexual Dysfunctions, Psychological
Lead sponsor: Sprout Pharmaceuticals, Inc
Sponsor class: INDUSTRY
First posted: 2007-03-01
Enrollment: 1723
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To determine if long-term treatment with Flibanserin is safe and to monitor the effectiveness of Flibanserin in Women with HSDD that have already completed a previous study (511.70/71/.74/.75/.105) with Flibanserin.


Eligibility criteria: Inclusion Criteria:

1. Women with a primary diagnosis of HSDD who have completed a previous study of Flibanserin.
2. Patients must have used a medically acceptable method of contraception for at least 2 months before the start of the study and continue to use that method for the duration of the study.
3. Patients must be reliable, compliant, and agree to cooperate with all study evaluations.
4. Patients must be able and willing to give meaningful, written informed consent prior to the start of the study and be willing to discuss their sexual functioning with the study staff.

Exclusion Criteria:

1. A history of Major Depressive Disorder within 6 months prior to the start of the study, current suicidal thoughts, or any history of a suicide attempt.
2. Participation in another clinical trial within 1 month prior to the start of the study, except for Flibanserin.
3. Patients with pelvic inflammatory disease, urinary tract infection, vaginal infection/vaginitis, cervicitis, interstitial cystitis, vulvodynia, or significant vaginal atrophy.
4. Patients who are pregnant or have been pregnant within 1 month prior to study start.
5. Patients experiencing major life stress (including loss of income, death of a family member, major illness, etc.) or relationship trouble that could interfere with sexual activity, except distress about HSDD.
6. Clinically significant ECG or lab abnormalities at study start.
7. Patients taking prohibited medications that were excluded in their previous trial which contribute to sexual dysfunction or safety-related interactions.

Primary outcomes:
measure: The Frequency of Adverse Events (Side Effects).
timeFrame: 52 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: 511.84.01079 Boehringer Ingelheim Investigational Site
state: Alabama
city: Birmingham
country: United States
facility: 511.84.01193 Boehringer Ingelheim Investigational Site
state: Alabama
city: Huntsville
country: United States
facility: 511.84.01188 Boehringer Ingelheim Investigational Site
state: Alabama
city: Mobile
country: United States
facility: 511.84.01110 Boehringer Ingelheim Investigational Site
state: Alabama
city: Mobile
country: United States
facility: 511.84.01142 Boehringer Ingelheim Investigational Site
state: Alabama
city: Mobile
country: United States
facility: 511.84.01157 Boehringer Ingelheim Investigational Site
state: Alabama
city: Little Rock
country: United States
facility: 511.84.01162 Boehringer Ingelheim Investigational Site
state: Alaska
city: Phoenix
country: United States
facility: 511.84.01070 Boehringer Ingelheim Investigational Site
state: Arizona
city: Phoenix
country: United States
facility: 511.84.01191 Boehringer Ingelheim Investigational Site
state: Arizona
city: Tucson
country: United States
facility: 511.84.01115 Boehringer Ingelheim Investigational Site
state: Arizona
city: Jonesboro
country: United States
facility: 511.84.01013 Boehringer Ingelheim Investigational Site
state: Arkansas
city: Berkeley
country: United States
facility: 511.84.01087 Boehringer Ingelheim Investigational Site
state: California
city: Encinitas
country: United States
facility: 511.84.01077 Boehringer Ingelheim Investigational Site
state: California
city: Fair Oaks
country: United States
facility: 511.84.01074 Boehringer Ingelheim Investigational Site
state: California
city: Irvine
country: United States
facility: 511.84.01104 Boehringer Ingelheim Investigational Site
state: California
city: La Jolla
country: United States
facility: 511.84.01037 Boehringer Ingelheim Investigational Site
state: California
city: Sacramento
country: United States
facility: 511.84.01056 Boehringer Ingelheim Investigational Site
state: California
city: Sacramento
country: United States
facility: 511.84.01195 Boehringer Ingelheim Investigational Site
state: California
city: San Diego
country: United States
facility: 511.84.01043 Boehringer Ingelheim Investigational Site
state: California
city: San Diego
country: United States
facility: 511.84.01047 Boehringer Ingelheim Investigational Site
state: California
city: San Diego
country: United States
facility: 511.84.01096 Boehringer Ingelheim Investigational Site
state: California
city: Stanford
country: United States
facility: 511.84.01040 Boehringer Ingelheim Investigational Site
state: California
city: Tarzana
country: United States
facility: 511.84.01048 Boehringer Ingelheim Investigational Site
state: California
city: Torrance
country: United States
facility: 511.84.01017 Boehringer Ingelheim Investigational Site
state: California
city: Vista
country: United States
facility: 511.84.01173 Boehringer Ingelheim Investigational Site
state: California
city: Walnut Creek
country: United States
facility: 511.84.01029 Boehringer Ingelheim Investigational Site
state: California
city: Westlake Village
country: United States
facility: 511.84.01137 Boehringer Ingelheim Investigational Site
state: California
city: Aurora
country: United States
facility: 511.84.01090 Boehringer Ingelheim Investigational Site
state: Colorado
city: Denver
country: United States
facility: 511.84.01164 Boehringer Ingelheim Investigational Site
state: Colorado
city: Denver
country: United States
facility: 511.84.01184 Boehringer Ingelheim Investigational Site
state: Colorado
city: Englewood
country: United States
facility: 511.84.01004 Boehringer Ingelheim Investigational Site
state: Colorado
city: Wheatridge
country: United States
facility: 511.84.01006 Boehringer Ingelheim Investigational Site
state: Colorado
city: Farmington
country: United States
facility: 511.84.01138 Boehringer Ingelheim Investigational Site
state: Connecticut
city: Groton
country: United States
facility: 511.84.01044 Boehringer Ingelheim Investigational Site
state: Connecticut
city: Hartford
country: United States
facility: 511.84.01016 Boehringer Ingelheim Investigational Site
state: Connecticut
city: New Britain
country: United States
facility: 511.84.01108 Boehringer Ingelheim Investigational Site
state: Connecticut
city: New London
country: United States
facility: 511.84.01168 Boehringer Ingelheim Investigational Site
state: Connecticut
city: Newark
country: United States
facility: 511.84.01166 Boehringer Ingelheim Investigational Site
state: Delaware
city: Washington
country: United States
facility: 511.84.01160 Boehringer Ingelheim Investigational Site
state: District of Columbia
city: Aventura
country: United States
facility: 511.84.01065 Boehringer Ingelheim Investigational Site
state: Florida
city: Boynton Beach
country: United States
facility: 511.84.01005 Boehringer Ingelheim Investigational Site
state: Florida
city: Clearwater
country: United States
facility: 511.84.01146 Boehringer Ingelheim Investigational Site
state: Florida
city: Coral Gables
country: United States
facility: 511.84.01144 Boehringer Ingelheim Investigational Site
state: Florida
city: Daytona Beach
country: United States
facility: 511.84.01169 Boehringer Ingelheim Investigational Site
state: Florida
city: Fort Lauderdale
country: United States
facility: 511.84.01085 Boehringer Ingelheim Investigational Site
state: Florida
city: Fort Meyers
country: United States
facility: 511.84.01194 Boehringer Ingelheim Investigational Site
state: Florida
city: Gainesville
country: United States
facility: 511.84.01002 Boehringer Ingelheim Investigational Site
state: Florida
city: Gainsville
country: United States
facility: 511.84.01069 Boehringer Ingelheim Investigational Site
state: Florida
city: Hudson
country: United States
facility: 511.84.01007 Boehringer Ingelheim Investigational Site
state: Florida
city: Miami
country: United States
facility: 511.84.01055 Boehringer Ingelheim Investigational Site
state: Florida
city: Miami
country: United States
facility: 511.84.01064 Boehringer Ingelheim Investigational Site
state: Florida
city: New Port Richey
country: United States
facility: 511.84.01182 Boehringer Ingelheim Investigational Site
state: Florida
city: Ocala
country: United States
facility: 511.84.01167 Boehringer Ingelheim Investigational Site
state: Florida
city: Orlando
country: United States
facility: 511.84.01111 Boehringer Ingelheim Investigational Site
state: Florida
city: Orlando
country: United States
facility: 511.84.01118 Boehringer Ingelheim Investigational Site
state: Florida
city: Pembroke Pines
country: United States
facility: 511.84.01135 Boehringer Ingelheim Investigational Site
state: Florida
city: Plantation
country: United States
facility: 511.84.01032 Boehringer Ingelheim Investigational Site
state: Florida
city: Sarasota
country: United States
facility: 511.84.01175 Boehringer Ingelheim Investigational Site
state: Florida
city: St. Petersburg
country: United States
facility: 511.84.01053 Boehringer Ingelheim Investigational Site
state: Florida
city: St. Petersburg
country: United States
facility: 511.84.01132 Boehringer Ingelheim Investigational Site
state: Florida
city: Stuart
country: United States
facility: 511.84.01117 Boehringer Ingelheim Investigational Site
state: Florida
city: Tampa
country: United States
facility: 511.84.01159 Boehringer Ingelheim Investigational Site
state: Florida
city: Tampa
country: United States
facility: 511.84.01170 Boehringer Ingelheim Investigational Site
state: Florida
city: Tampa
country: United States
facility: 511.84.01183 Boehringer Ingelheim Investigational Site
state: Florida
city: West Palm Beach
country: United States
facility: 511.84.01003 Boehringer Ingelheim Investigational Site
state: Florida
city: West Palm Beach
country: United States
facility: 511.84.01022 Boehringer Ingelheim Investigational Site
state: Florida
city: Atlanta
country: United States
facility: 511.84.01024 Boehringer Ingelheim Investigational Site
state: Georgia
city: Atlanta
country: United States
facility: 511.84.01061 Boehringer Ingelheim Investigational Site
state: Georgia
city: Atlanta
country: United States
facility: 511.84.01205 Boehringer Ingelheim Investigational Site
state: Georgia
city: Marietta
country: United States
facility: 511.84.01176 Boehringer Ingelheim Investigational Site
state: Georgia
city: Roswell
country: United States
facility: 511.84.01139 Boehringer Ingelheim Investigational Site
state: Georgia
city: Sandy Springs
country: United States
facility: 511.84.01023 Boehringer Ingelheim Investigational Site
state: Georgia
city: Champaign
country: United States
facility: 511.84.01179 Boehringer Ingelheim Investigational Site
state: Illinois
city: Chicago
country: United States
facility: 511.84.01113 Boehringer Ingelheim Investigational Site
state: Illinois
city: Chicago
country: United States
facility: 511.84.01165 Boehringer Ingelheim Investigational Site
state: Illinois
city: Chicago
country: United States
facility: 511.84.01172 Boehringer Ingelheim Investigational Site
state: Illinois
city: Evansville
country: United States
facility: 511.84.01143 Boehringer Ingelheim Investigational Site
state: Indiana
city: Indianapolis
country: United States
facility: 511.84.01092 Boehringer Ingelheim Investigational Site
state: Indiana
city: Wichita
country: United States
facility: 511.84.01202 Boehringer Ingelheim Investigational Site
state: Kansas
city: Lexington
country: United States
facility: 511.84.01049 Boehringer Ingelheim Investigational Site
state: Kentucky
city: Baton Rouge
country: United States
facility: 511.84.01025 Boehringer Ingelheim Investigational Site
state: Louisiana
city: Lafayette
country: United States
facility: 511.84.01171 Boehringer Ingelheim Investigational Site
state: Louisiana
city: New Orleans
country: United States
facility: 511.84.01192 Boehringer Ingelheim Investigational Site
state: Louisiana
city: New Orlean
country: United States
facility: 511.84.01130 Boehringer Ingelheim Investigational Site
state: Louisiana
city: Baltimore
country: United States
facility: 511.84.01001 Boehringer Ingelheim Investigational Site
state: Maryland
city: Brighton
country: United States
facility: 511.84.01120 Boehringer Ingelheim Investigational Site
state: Massachusetts
city: Haverhill
country: United States
facility: 511.84.01030 Boehringer Ingelheim Investigational Site
state: Massachusetts
city: Ann Arbor
country: United States
facility: 511.84.01127 Boehringer Ingelheim Investigational Site
state: Michigan
city: Bingham Farms
country: United States
facility: 511.84.01081 Boehringer Ingelheim Investigational Site
state: Michigan
city: Bingham Farms
country: United States
facility: 511.84.01147 Boehringer Ingelheim Investigational Site
state: Michigan
city: Detroit
country: United States
facility: 511.84.01041 Boehringer Ingelheim Investigational Site
state: Michigan
city: Chaska
country: United States
facility: 511.84.01131 Boehringer Ingelheim Investigational Site
state: Minnesota
city: Chesterfield
country: United States
facility: 511.84.01128 Boehringer Ingelheim Investigational Site
state: Missouri
city: Kansas City
country: United States
facility: 511.84.01051 Boehringer Ingelheim Investigational Site
state: Missouri
city: St. Louis
country: United States
facility: 511.84.01034 Boehringer Ingelheim Investigational Site
state: Missouri
city: Billings
country: United States
facility: 511.84.01042 Boehringer Ingelheim Investigational Site
state: Montana
city: Omaha
country: United States
facility: 511.84.01156 Boehringer Ingelheim Investigational Site
state: Nebraska
city: Las Vegas
country: United States
facility: 511.84.01148 Boehringer Ingelheim Investigational Site
state: Nevada
city: Moorestown
country: United States
facility: 511.84.01206 Boehringer Ingelheim Investigational Site
state: New Jersey
city: New Brunswick
country: United States
facility: 511.84.01010 Boehringer Ingelheim Investigational Site
state: New Jersey
city: Albequerque
country: United States
facility: 511.84.01045 Boehringer Ingelheim Investigational Site
state: New Mexico
city: Bronx
country: United States
facility: 511.84.01059 Boehringer Ingelheim Investigational Site
state: New York
city: Endwell
country: United States
facility: 511.84.01050 Boehringer Ingelheim Investigational Site
state: New York
city: Poughkeepsie
country: United States
facility: 511.84.01066 Boehringer Ingelheim Investigational Site
state: New York
city: Purchase
country: United States
facility: 511.84.01187 Boehringer Ingelheim Investigational Site
state: New York
city: Rochester
country: United States
facility: 511.84.01038 Boehringer Ingelheim Investigational Site
state: New York
city: Chapel Hill
country: United States
facility: 511.84.01178 Boehringer Ingelheim Investigational Site
state: North Carolina
city: New Bern
country: United States
facility: 511.84.01121 Boehringer Ingelheim Investigational Site
state: North Carolina
city: Raleigh
country: United States
facility: 511.84.01119 Boehringer Ingelheim Investigational Site
state: North Carolina
city: Winston-Salem
country: United States
facility: 511.84.01072 Boehringer Ingelheim Investigational Site
state: North Carolina
city: Beachwood
country: United States
facility: 511.84.01106 Boehringer Ingelheim Investigational Site
state: Ohio
city: Cincinnati
country: United States
facility: 511.84.01008 Boehringer Ingelheim Investigational Site
state: Ohio
city: Cincinnati
country: United States
facility: 511.84.01062 Boehringer Ingelheim Investigational Site
state: Ohio
city: Cincinnati
country: United States
facility: 511.84.01089 Boehringer Ingelheim Investigational Site
state: Ohio
city: Cincinnati
country: United States
facility: 511.84.01197 Boehringer Ingelheim Investigational Site
state: Ohio
city: Cincinnati
country: United States
facility: 511.84.01201 Boehringer Ingelheim Investigational Site
state: Ohio
city: Cleveland
country: United States
facility: 511.84.01009 Boehringer Ingelheim Investigational Site
state: Ohio
city: Cleveland
country: United States
facility: 511.84.01014 Boehringer Ingelheim Investigational Site
state: Ohio
city: Cleveland
country: United States
facility: 511.84.01152 Boehringer Ingelheim Investigational Site
state: Ohio
city: Columbus
country: United States
facility: 511.84.01136 Boehringer Ingelheim Investigational Site
state: Ohio
city: Columbus
country: United States
facility: 511.84.01149 Boehringer Ingelheim Investigational Site
state: Ohio
city: Columbus
country: United States
facility: 511.84.01151 Boehringer Ingelheim Investigational Site
state: Ohio
city: Dayton
country: United States
facility: 511.84.01150 Boehringer Ingelheim Investigational Site
state: Ohio
city: Oklahoma City
country: United States
facility: 511.84.01190 Boehringer Ingelheim Investigational Site
state: Oklahoma
city: Tulsa
country: United States
facility: 511.84.01112 Planned Parenthood of Arkansas & Estrn Oklahoma, Inc
state: Oklahoma
city: Tulsa
country: United States
facility: 511.84.01185 Boehringer Ingelheim Investigational Site
state: Oklahoma
city: Eugene
country: United States
facility: 511.84.01019 Boehringer Ingelheim Investigational Site
state: Oregon
city: Medfod
country: United States
facility: 511.84.01134 Boehringer Ingelheim Investigational Site
state: Oregon
city: Portland
country: United States
facility: 511.84.01103 Boehringer Ingelheim Investigational Site
state: Oregon
city: Jenkintown
country: United States
facility: 511.84.01088 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Philadelphia
country: United States
facility: 511.84.01067 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Philadelphia
country: United States
facility: 511.84.01153 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Pittsburgh
country: United States
facility: 511.84.01145 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: West Reading
country: United States
facility: 511.84.01054 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Wilkes-Barre
country: United States
facility: 511.84.01021 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Warwick
country: United States
facility: 511.84.01060 Boehringer Ingelheim Investigational Site
state: Rhode Island
city: Anderson
country: United States
facility: 511.84.01063 Boehringer Ingelheim Investigational Site
state: South Carolina
city: Columbia
country: United States
facility: 511.84.01124 Boehringer Ingelheim Investigational Site
state: South Carolina
city: Greenville
country: United States
facility: 511.84.01123 Boehringer Ingelheim Investigational Site
state: South Carolina
city: Mt. Pleasant
country: United States
facility: 511.84.01109 Boehringer Ingelheim Investigational Site
state: South Carolina
city: Germantown
country: United States
facility: 511.84.01174 Boehringer Ingelheim Investigational Site
state: Tennessee
city: Knoxville
country: United States
facility: 511.84.01163 Boehringer Ingelheim Investigational Site
state: Tennessee
city: Nashville
country: United States
facility: 511.84.01026 Boehringer Ingelheim Investigational Site
state: Tennessee
city: Nashville
country: United States
facility: 511.84.01100 Boehringer Ingelheim Investigational Site
state: Tennessee
city: Austin
country: United States
facility: 511.84.01078 Boehringer Ingelheim Investigational Site
state: Texas
city: Corpus Christi
country: United States
facility: 511.84.01052 Boehringer Ingelheim Investigational Site
state: Texas
city: Dallas
country: United States
facility: 511.84.01027 Boehringer Ingelheim Investigational Site
state: Texas
city: Dallas
country: United States
facility: 511.84.01140 Boehringer Ingelheim Investigational Site
state: Texas
city: Fort Worth
country: United States
facility: 511.84.01084 Boehringer Ingelheim Investigational Site
state: Texas
city: Houston
country: United States
facility: 511.84.01057 Boehringer Ingelheim Investigational Site
state: Texas
city: Houston
country: United States
facility: 511.84.01082 Boehringer Ingelheim Investigational Site
state: Texas
city: Houston
country: United States
facility: 511.84.01198 Boehringer Ingelheim Investigational Site
state: Texas
city: San Antonio
country: United States
facility: 511.84.01036 Boehringer Ingelheim Investigational Site
state: Texas
city: San Antonio
country: United States
facility: 511.84.01071 Boehringer Ingelheim Investigational Site
state: Texas
city: San Antonio
country: United States
facility: 511.84.01083 Boehringer Ingelheim Investigational Site
state: Texas
city: San Antonio
country: United States
facility: 511.84.01086 Boehringer Ingelheim Investigational Site
state: Texas
city: Waco
country: United States
facility: 511.84.01098 Boehringer Ingelheim Investigational Site
state: Texas
city: Salt Lake City
country: United States
facility: 511.84.01015 Boehringer Ingelheim Investigational Site
state: Utah
city: Sandy
country: United States
facility: 511.84.01180 Boehringer Ingelheim Investigational Site
state: Utah
city: Burlington
country: United States
facility: 511.84.01028 Boehringer Ingelheim Investigational Site
state: Vermont
city: Charlottesville
country: United States
facility: 511.84.01031 Boehringer Ingelheim Investigational Site
state: Virginia
city: Charlottesville
country: United States
facility: 511.84.01035 Boehringer Ingelheim Investigational Site
state: Virginia
city: Norfolk
country: United States
facility: 511.84.01107 Boehringer Ingelheim Investigational Site
state: Virginia
city: Norfolk
country: United States
facility: 511.84.01125 Boehringer Ingelheim Investigational Site
state: Virginia
city: Richmond
country: United States
facility: 511.84.01076 Boehringer Ingelheim Investigational Site
state: Virginia
city: Richmond
country: United States
facility: 511.84.01097 Boehringer Ingelheim Investigational Site
state: Virginia
city: Richmond
country: United States
facility: 511.84.01196 Boehringer Ingelheim Investigational Site
state: Virginia
city: Bellevue
country: United States
facility: 511.84.01093 Boehringer Ingelheim Investigational Site
state: Washington
city: Renton
country: United States
facility: 511.84.01141 Boehringer Ingelheim Investigational Site
state: Washington
city: Seattle
country: United States
facility: 511.84.01012 Boehringer Ingelheim Investigational Site
state: Washington
city: Spokane
country: United States
facility: 511.84.01116 Boehringer Ingelheim Investigational Site
state: Washington
city: Tacoma
country: United States
facility: 511.84.01105 Boehringer Ingelheim Investigational Site
state: Washington
city: Middleton
country: United States
facility: 511.84.01177 Boehringer Ingelheim Investigational Site
state: Wisconsin
city: Calgary
country: Canada
facility: 511.84.02007 Boehringer Ingelheim Investigational Site
state: Alberta
city: Coquitlam
country: Canada
facility: 511.84.02014 Boehringer Ingelheim Investigational Site
state: British Columbia
city: North Vancouver
country: Canada
facility: 511.84.02002 Boehringer Ingelheim Investigational Site
state: British Columbia
city: Surrey
country: Canada
facility: 511.84.02021 Boehringer Ingelheim Investigational Site
state: British Columbia
city: Vancouver
country: Canada
facility: 511.84.02013 Boehringer Ingelheim Investigational Site
state: British Columbia
city: Victoria
country: Canada
facility: 511.84.02015 Boehringer Ingelheim Investigational Site
state: British Columbia
city: Victoria
country: Canada
facility: 511.84.02023 Boehringer Ingelheim Investigational Site
state: British Columbia
city: Winnipeg
country: Canada
facility: 511.84.02017 Boehringer Ingelheim Investigational Site
state: Manitoba
city: Woodstock
country: Canada
facility: 511.84.02010 Boehringer Ingelheim Investigational Site
state: New Brunswick
city: Mount Pearl
country: Canada
facility: 511.84.02012 Boehringer Ingelheim Investigational Site
state: Newfoundland and Labrador
city: St. John's
country: Canada
facility: 511.84.02006 Boehringer Ingelheim Investigational Site
state: Newfoundland and Labrador
city: Halifax
country: Canada
facility: 511.84.02003 Boehringer Ingelheim Investigational Site
state: Nova Scotia
city: Barrie
country: Canada
facility: 511.84.02018 Boehringer Ingelheim Investigational Site
state: Ontario
city: Burlington
country: Canada
facility: 511.84.02009 Boehringer Ingelheim Investigational Site
state: Ontario
city: London
country: Canada
facility: 511.84.02022 Boehringer Ingelheim Investigational Site
state: Ontario
city: London
country: Canada
facility: 511.84.02024 Boehringer Ingelheim Investigational Site
state: Ontario
city: Ottawa
country: Canada
facility: 511.84.02001 Boehringer Ingelheim Investigational Site
state: Ontario
city: Ottawa
country: Canada
facility: 511.84.02008 Boehringer Ingelheim Investigational Site
state: Ontario
city: Montréal
country: Canada
facility: 511.84.02011 Boehringer Ingelheim Investigational Site
state: Quebec
city: Québec
country: Canada
facility: 511.84.02019 Boehringer Ingelheim Investigational Site
state: Quebec
city: Sherbrooke
country: Canada
facility: 511.84.02005 Boehringer Ingelheim Investigational Site
state: Quebec
city: Saskatoon
country: Canada
facility: 511.84.02004 Boehringer Ingelheim Investigational Site
state: Saskatchewan
city: Quebec
country: Canada
facility: 511.84.02020 Boehringer Ingelheim Investigational Site
Study officials:
affiliation: Boehringer Ingelheim
name: Boehringer Ingelheim
role: STUDY_CHAIR
References:
citation: Jayne C, Simon JA, Taylor LV, Kimura T, Lesko LM; SUNFLOWER study investigators. Open-label extension study of flibanserin in women with hypoactive sexual desire disorder. J Sex Med. 2012 Dec;9(12):3180-8. doi: 10.1111/j.1743-6109.2012.02942.x. Epub 2012 Oct 11.